Free · 13,591 studies indexed

lighttherapyresearch.com is a free index of research on photobiomodulation and light therapy, gathered from the world’s journals and trial registries.

Sections
Brain & Neurology

Modulating cerebrospinal fluid dynamics using pulsed photobiomodulation

AI-generated summary

The authors studied 45 healthy young adults using forehead and intranasal photobiomodulation while measuring cerebrospinal fluid dynamics with functional MRI. They report that as little as four minutes of light was associated with an immediate increase in intracranial CSF volume and reduced CSF inflow. Lighter skin was linked to larger responses, and the authors suggest further work is needed in patient populations.

Participants
45
Who or what was studied
45 healthy young adults
Limits stated in the abstract
The abstract states that the influence of melanin, the feasibility of intranasal PBM and dose dependence will require further investigation in healthy and patient populations.

Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.

Abstract

Introduction

The use of photobiomodulation (PBM) to enhance brain health, specifically glymphatic drainage and thus neurotoxic waste clearance, may make it a promising therapeutic tool against neurodegenerative diseases such as Alzheimer's disease. MATERIAL AND

Method

This study investigates whether PBM can modulate cerebrospinal fluid (CSF) flow in 45 healthy young adults. We conducted forehead transcranial PBM (tPBM) and intranasal PBM (iPBM) at the nostril, and measured CSF dynamics using blood-oxygenation level-dependent (BOLD) functional MRI (fMRI). Our data demonstrates 4 min of PBM-induced increases in CSF flow.

Conclusion And Result

Our data shows that (1) even a short PBM of 4 min can induce a change in CSF dynamics, in the form of an immediate increase in intracranial CSF volume and a reduction in CSF inflow; (2) skin melanin had a significant effect on the CSF response in tPBM, with lighter skin associated with higher responses; (3) both iPBM and tPBM displayed a dose-dependent effect on CSF dynamics in terms of a wavelength-irradiance interaction; (4) intranasal PBM (iPBM) can be used to produce a significant change in CSF dynamics that is equivalent to forehead transcranial PBM (tPBM) with a small fraction of the irradiance. The most likely explanation for the observed fMRI signal changes in CSF regions of interest for both tPBM and iPBM is an increased CSF outflow pressure due to PBM-induced vasodilation that transiently increases intracranial CSF volume and reduces net CSF inflow. IMPACT: This study establishes that PBM can modulate CSF flow in the healthy human brain in real time. This study also suggests that iPBM may be more efficient in CSF modulation due to the proximity to the olfactory system and the lack of melanin dependence. The influence of melanin on tPBM, the feasibility of iPBM and the dose dependence of both will require further investigation in healthy and patient populations.

Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.

How to read a single study: what to check before relying on this kind of research.

Terms in this paper: Photobiomodulation, Transcranial photobiomodulation, Intranasal photobiomodulation, Melanin, Functional magnetic resonance imaging, Irradiance, Dose, Wavelength. Each links to its definition in the glossary.

A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.

Related studies

Brain & Neurology

A multimodal evaluation of transcranial photobiomodulation in mild cognitive impairment: Cognitive, metabolic, and neuroimaging outcomes of a pilot randomized controlled trial

Cognitive, metabolic, and network-level findings are consistent with enhanced mitochondrial efficiency and anti-inflammatory effects. These results support larger, double-blind, multicenter trials to evaluate tPBM as a mitochondria-targeted therapy in early ADRD.

Trial · June 3, 2026 · Rashidi-Ranjbar N et al.